Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 06-2023 | 03-2023 | |
| Sales | 2,279 | 1,401 | 0 | 0 | 8,629 |
| Gross Profit | 2,279 | 1,401 | N/A | N/A | 8,629 |
| Operating Expenses | 54,854 | 56,883 | 0 | 0 | 48,482 |
| Operating Income | -52,575 | -55,482 | N/A | N/A | -39,853 |
| Other Income | 13,568 | -38,285 | 0 | 0 | -2,165 |
| Pre-tax Income | -39,007 | -93,767 | 0 | 0 | -42,018 |
| Net Income Continuous | -39,007 | -93,767 | N/A | N/A | -42,018 |
| Net Income | $-39,007 | $-93,767 | $N/A | $N/A | $-42,018 |
| EPS Basic Total Ops | -0.41 | -1.06 | N/A | N/A | -0.51 |
| EPS Basic Continuous Ops | -0.41 | -1.06 | N/A | N/A | -0.51 |
| EPS Diluted Total Ops | -0.41 | -1.06 | N/A | N/A | -0.51 |
| EPS Diluted Continuous Ops | -0.41 | -1.06 | N/A | N/A | -0.51 |
| EPS Diluted Before Non-Recurring Items | -0.51 | -0.62 | N/A | N/A | N/A |
| EBITDA(a) | $-52,556 | $-55,467 | $N/A | $N/A | $-39,844 |